Brind.

The FDA approved label updates for Bristol Myers Squibb's therapies, noting the company's development and marketing of CAR T cell therapies.

3 reports, 1 independent Updated Jun 30

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The FDA approved label updates for Bristol Myers Squibb's therapies, noting the company's development and marketing of CAR T cell therapies.

Who's involved

What this event is mainly about

FDA CAR Bristol-Myers Squibb

Keep exploring

The entities involved

FDA
- HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.21:18
- The National Center for PTSD provides data on PTSD in the US while university researchers develop FDA-cleared treatments.21:09
CAR
Nothing else this week.
Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb presented clinical data at the European Society for Medical Oncology (ESMO) Congress in Madrid.Sun 09:20
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.Sat 18:36

Related events

Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.Oct 21
Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.Jun 7
Generic medicine services are seeking approval for launch from the FDA.Sep 28

Coverage

Newest first; wire copies grouped

Jun 30yahoo.com
Jun 27Unknown outlet
Jun 27Unknown outlet